Aarti Pharmalabs Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Revenue +9% YoY, CDMO hits quarterly record: Q4 revenue driven by Xanthine derivatives (Rs.227 Cr, 43% of turnover) and CDMO/CMO (Rs.155 Cr, 29% of turnover), both at all-time quarterly highs.
• Margin pressure from capacity front-loading: EBITDA margins contracted YoY as ~700 KL of new multipurpose capacity came online with full costs but partial revenue; management does not expect margins to fall below 20%.
• CDMO poised for breakout, but customer count stalled: Full-year CDMO revenue grew 32% YoY with FY27 guidance of 40–50% growth, yet the customer count has stayed at 21 for five straight quarters.
• API/Intermediates had a soft year, recovery expected: Revenue fell from ~Rs.772 Cr to ~Rs.647 Cr on feedstock inflation and inability to pass through costs; management expects a return to FY25 levels in FY27.
• What to watch next quarter: Whether the CDMO customer count finally expands, the pace of Xanthine ramp-up toward 9,000 MTPA, and how much the step-jump in operational costs from Q2 FY27 pressures margins.

CDMO/CMO: The Growth Engine

• Record quarter, lumpy by nature: Q4 CDMO revenue of Rs.155 Cr was inflated by a consignment that slipped from the prior quarter; the underlying run-rate was closer to Rs.100 Cr per quarter. Nearly all revenue comes from phase 3 and commercial molecules, consistent with the late-phase focus.
• FY27 growth ambition is aggressive: Management projects 40–50% sales growth in FY27 and has line of sight to close to USD 100 million in the segment, though no firm timeline is given for reaching that number. The Rs.1,000 Cr target depends on customer projections and product launches.
• Customer concentration risk sits alongside the growth story: The customer count has remained at 21 for five consecutive quarters. Management expects this number to grow in the current financial year, but the static count means current growth relies on deepening existing relationships.
• Dedicated block economics are shifting: A dedicated manufacturing block at Atali, tailored to a specific project, is in preliminary design. Management now estimates a capex turnover of 1.5x to 2x, revised up from an earlier 1–1.2x, with potential topline of Rs.250–300 Cr from a single block. Completion is expected 12 months from construction start.
• Working capital will rise with project scale: Large CDMO projects involve one-time or two-time deliveries per year, and customers do not pay advances, so working capital is expected to increase.

Gogri: "These custom-built facilities, of course, have the starting reactors, which can also be made multipurpose also in future, if there are any issues with these customers, but largely, I think we are following with their guidance and as long as we continue to work and meet the customer's expectations on quality and the deliverables, I think we will continue to get more revenue from these customers."

Xanthine Derivatives: Capacity-Led Growth, Margin Trade-Off

• Q4 revenue was both volume-led and price-led: Xanthine revenue hit Rs.227 Cr, the highest ever, with current 6,000 MTPA capacity fully utilized at 500 tonnes per month.
• Expansion timeline is near-term: Incremental final product capacity will be available at the end of the current quarter (Q1 FY27), with a gradual ramp-up to 9,000 MTPA over the next few quarters. FY27 revenue of Rs.1,000 Cr is possible, and peak revenue can go well beyond that.
• Margin dilution is built into the growth plan: Currently, the business captures marquee customers. As higher capacities come online, the company will need to go after the spot market where competition is more intense, so EBITDA growth will not match revenue growth.
• Pricing power exists but has limits: The company is requesting proportionate price increases from customers to offset raw material costs. Chinese competitors face 11–13% export rebates and 20%+25% tariffs, creating a pricing umbrella, but management was cut off before quantifying the benefit.

Gogri: "In Xanthine, currently we are capturing all the marquee customers. As our higher capacities will come, we will have to go after more spot market, where of course, we have to fight with our competitor and get that volume. That is where definitely the top line growth will come. But overall, I think EBITDA growth will not catch up to that level."

API & Intermediates: A Soft Year, A Modest Rebound

• FY26 was a down year: Revenue declined from ~Rs.772 Cr in FY25 to ~Rs.647 Cr in FY26, hurt by inventory issues at customers, feedstock inflation, and an inability to pass through costs on existing high-value, low-volume orders.
• Recovery is expected, not yet evidenced: Management expects growth in FY27 and a return to FY25 revenue levels, but the segment remains exposed to competitive pricing pressure where cost pass-through is structurally difficult. New inquiries are now being quoted at revised cost bases with improved pricing.
• Geopolitics added cost and logistics friction: War and tension in West Asia created logistics hurdles and rising energy costs. The intermediate segment, where competitive pricing makes cost pass-through difficult, bore the brunt; CDMO and Xanthine segments were reasonably able to pass cost hikes.
• Solvent recycling provides partial mitigation: In API, the raw material cost impact is largely on solvents, and the company's solvent recycling capabilities offer some offset.

Capacity Build-Out & Capex

• ~700 KL of new multipurpose capacity is coming online now: ~440 KL at Atali and ~250 KL at a leased site will be on the books from Q1 FY27, representing a 70% increase in capacity. Costs are fully loaded from day one while revenue ramps gradually.
• Atali phase 1 is largely past startup issues: Corrective actions are majorly in place, production scale-up is progressing, and customer audits have been cleared. The remaining small block will be fully capitalized in Q1 FY27. The site is positioned to support both CDMO and intermediate production.
• Capex stays elevated for FY27, then declines: Management plans ~Rs.400 Cr of capex in FY27, spread across Xanthine completion, Atali phase 1 capitalization, Atali phase 2, debottlenecking, replacement capex, and R&D. Capex intensity is expected to come down from FY28 onward as future expansion shifts to brownfield with lower cost.
• Steroid block debottlenecking is done: Tarapur Unit-4 capacity increased by about one-third, with more brownfield initiatives planned in FY27 to expand anti-cancer and other blocks.
• R&D investment in tides is a long-dated bet: The company is investing in peptide and oligonucleotide R&D, which will not yield immediate results but has good future potential.

Margins: Cost Step-Up Before Operating Leverage

• New capacity is a margin drag until it fills: EBITDA margins contracted YoY because new facilities added costs at full capacity while ramp-up takes time. Management confirmed there were no one-offs from Atali; the pressure is structural and front-loaded.
• A step-jump in operational costs is coming from Q2 FY27: As Xanthine expansion and Atali phase 1 completion get fully capitalized and operational, OpEx will rise, driven by ~700 KL of new capacity and 50–60% more man-hours. Management does not expect margins to go below 20%.
• Normalization will take at least a year: Meaningful EBITDA contribution from current capex is expected only from FY27 Q1 onward, implying a full-year lag before operating leverage kicks in.
• CDMO commercialization brings its own margin math: As products commercialize, volume and value can grow faster but with lower margin expectations on commercialized products, so blended margins may shift.
• Forex was a net P&L drag: A Rs.33 Cr notional loss on foreign currency loans was partially offset by a Rs.22 Cr gain on export/import operations, for a net Rs.17 Cr total forex loss, excluded from EBITDA. Foreign currency exposure is fully accounted for six to eight months forward.

Guidance & Commitments

Key Metrics